Hence, discovering new biomarkers that can reflect PD-L1 expression levels and the density of tumor-infiltrating lymphocytes (TILs) might effectively predict the effectiveness of blocking PD-1/PD-L1 and the correlation with anti-PD-L1 therapy [35]. The gene discussed is CD274; the disease is neoplasm.